Andrew X. Zhu - Concepedia

Author

Andrew X. Zhu

Massachusetts General Hospital ORCID

Also Known As

A Zhu, A. X. Zhu, A. Zhu, A.X. Zhu, Andrew X Zhu, Andrew X. Zhu, Andrew Zhu, Andrew X. Zhu, Anquan Zhu, Audrey Zhu

103

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Massachusetts General Hospital Harvard University Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center National Taiwan University Hospital

About

Andrew X. Zhu is an author at Massachusetts General Hospital specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	569
2	Health Sciences	5	5	105
3	Natural Sciences	2	2	276
4	Engineering	1	1	29
5	Cell Biology	1	1	247

Andrew X. Zhu

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline John D. Gordan, Erin B. Kennedy, Ghassan K. Abou‐Alfa, Journal of Clinical Oncology	2020	601
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial Robin Kate Kelley, Lorenza Rimassa, Ann‐Lii Cheng, The Lancet Oncology	2022	494
YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression Julien Fitamant, Filippos Kottakis, Samira Benhamouche, Cell Reports Tumor RegressionPathologyHcc PathogenesisDefective Hippo/yap SignalingCancer Biology	2015	247
Differentiation of Malignant Thrombus from Bland Thrombus of the Portal Vein in Patients with Hepatocellular Carcinoma: Application of Diffusion-weighted MR Imaging Onofrio A. Catalano, Garry Choy, Andrew X. Zhu, Radiology	2009	205
Gemcitabine‐associated thrombotic microangiopathy Benjamin D. Humphreys, Jeff P. Sharman, Joel Henderson, Cancer	2004	178
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma Vikram Deshpande, Afamefuna Nduaguba, Stephanie M. Zimmerman, BMC Cancer	2011	95
A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma Lipika Goyal, Hui Zheng, Thomas A. Abrams, Clinical Cancer Research	2018	79
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer J. A. Meyerhardt, Keith Stuart, Christiane Fuchs, Annals of Oncology Metastastic Colorectal CancerFirst-line TherapyMedicinePathologyColorectal Cancer	2007	78
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors Stephen L. Chan, Martin Schüler, Yoon‐Koo Kang, Journal of Experimental & Clinical Cancer Research	2022	71
LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma Shukui Qin, Masashi Kudo, T Meyer, Annals of Oncology HepatologyMedicinePathologyLba36 Final AnalysisMolecular Oncology	2022	66

Page 1